Affordable Access

Publisher Website

Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.

Authors
Type
Published Article
Journal
Clinical Cancer Research
1078-0432
Publisher
American Association for Cancer Research
Publication Date
Volume
19
Issue
15
Pages
4282–4289
Identifiers
DOI: 10.1158/1078-0432.CCR-12-1840
PMID: 23741071
Source
Medline

Abstract

Baseline circulating factors of the IGF axis may predict OS benefit from ganitumab plus gemcitabine in metastatic pancreatic adenocarcinoma.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments
F